SHP 465

Drug Profile

SHP 465

Alternative Names: Amphetamine salts (mixed, long acting) - Shire; d,l-Amphetamine and d-amphetamine salts (long acting) - Shire; d,l-Amphetamine and dextroamphetamine salts (long acting) - Shire; d-Amphetamine and d,l-amphetamine salts (long acting) - Shire; Dextroamphetamine and d,l-amphetamine salts (long acting) - Shire; SHP-465; SLI 381 XR; SPD465; Triple-bead mixed amphetamine salts - Shire

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Shire
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 29 Jun 2016 Safety and efficacy data from the phase III SHP465-306 trial in Attention-deficit hyperactivity disorder released by Shire
  • 04 Apr 2016 Shire initiates enrolment in a phase III trial for Attention-deficit hyperactivity disorder (In adults) in USA before April 2016
  • 01 Mar 2016 Shire completes a phase III trial for Attention-deficit hyperactivity disorder in USA (PO) (NCT02604407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top